India’s Sharp Increase In Type 2 Diabetes Boon To Drug Makers
This article was originally published in PharmAsia News
Makers of drugs for diabetics report a 17 percent increase in sales in the 12-month period ending in August. Diabetic drugs also have increased from 4.6 percent of the drug market in India to 5.1 percent, according to ORG IMS. The increase, according to authorities, is due to the fact India has the world's largest population of diabetics, particularly Type 2 diabetes, which is expected to afflict more than 60 million people by 2017, up from 28 million last year. The numbers have led to an increasing number of drug makers entering that sector of the market, with GlaxoSmithKline expected to launch the first molecule for treatment within two years. (Click here for more
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.